Show simple item record

dc.contributor.authorVan den Bergh, R
dc.contributor.authorChaillet, P
dc.contributor.authorSow, MS
dc.contributor.authorAmand, M
dc.contributor.authorvan Vyve, C
dc.contributor.authorJonckheere, S
dc.contributor.authorCrestani, R
dc.contributor.authorSprecher, A
dc.contributor.authorVan Herp, M
dc.contributor.authorChua, A
dc.contributor.authorPiriou, E
dc.contributor.authorKoivogui, L
dc.contributor.authorAntierens, A
dc.date.accessioned2016-03-28T16:41:12Zen
dc.date.available2016-03-28T16:41:12Zen
dc.date.issued2016-02-01en
dc.identifier.citationFeasibility of Xpert Ebola Assay in Médecins Sans Frontières Ebola Program, Guinea. 2016, 22 (2):210-2106 Emerging Infect. Dis.en
dc.identifier.issn1080-6059en
dc.identifier.pmid26812466en
dc.identifier.doi10.3201/eid2202.151238en
dc.identifier.urihttp://hdl.handle.net/10144/603738en
dc.description.abstractRapid diagnostic methods are essential in control of Ebola outbreaks and lead to timely isolation of cases and improved epidemiologic surveillance. Diagnosis during Ebola outbreaks in West Africa has relied on PCR performed in laboratories outside this region. Because time between sampling and PCR results can be considerable, we assessed the feasibility and added value of using the Xpert Ebola Assay in an Ebola control program in Guinea. A total of 218 samples were collected during diagnosis, treatment, and convalescence of patients. Median time for obtaining results was reduced from 334 min to 165 min. Twenty-six samples were positive for Ebola virus. Xpert cycle thresholds were consistently lower, and 8 (31%) samples were negative by routine PCR. Several logistic and safety issues were identified. We suggest that implementation of the Xpert Ebola Assay under programmatic conditions is feasible and represents a major advance in diagnosis of Ebola virus disease without apparent loss of assay sensitivity.
dc.language.isoenen
dc.publisherCenter for Disease Control and Preventionen
dc.rightsPublished by Centers for Disease Control (CDC) Archived on this site by permission of CDC, [url]http://www.cdc.gov/ncidod/eid[/url]en
dc.titleFeasibility of Xpert Ebola Assay in Médecins Sans Frontières Ebola Program, Guineaen
dc.typeArticleen
dc.identifier.journalEmerging Infectious Diseasesen
refterms.dateFOA2019-03-04T12:41:51Z
html.description.abstractRapid diagnostic methods are essential in control of Ebola outbreaks and lead to timely isolation of cases and improved epidemiologic surveillance. Diagnosis during Ebola outbreaks in West Africa has relied on PCR performed in laboratories outside this region. Because time between sampling and PCR results can be considerable, we assessed the feasibility and added value of using the Xpert Ebola Assay in an Ebola control program in Guinea. A total of 218 samples were collected during diagnosis, treatment, and convalescence of patients. Median time for obtaining results was reduced from 334 min to 165 min. Twenty-six samples were positive for Ebola virus. Xpert cycle thresholds were consistently lower, and 8 (31%) samples were negative by routine PCR. Several logistic and safety issues were identified. We suggest that implementation of the Xpert Ebola Assay under programmatic conditions is feasible and represents a major advance in diagnosis of Ebola virus disease without apparent loss of assay sensitivity.


Files in this item

Thumbnail
Name:
Van den Bergh et al - 2016 - ...
Size:
564.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record